An esterase-activated magnetic resonance contrast agent.

Area of Science:

• Biomedical imaging
• Contrast agents
• Gadolinium complexes

Background:

• Gadolinium (Gd(III)) complexes are widely used as magnetic resonance imaging (MRI) contrast agents.
• Their efficacy is often limited by relaxivity, which quantifies their ability to enhance the MRI signal.
• Developing activatable contrast agents that respond to specific biological conditions is an active area of research.

Purpose of the Study:

• To synthesize and characterize a Gd(III) complex with pendant acetoxymethyl ester groups designed for enzyme-triggered activation.
• To investigate the effect of enzymatic activation on the relaxivity of the Gd(III) complex.
• To elucidate the mechanism behind the observed relaxivity changes upon activation.

Main Methods:

• Synthesis of a Gd(III) complex featuring acetoxymethyl ester functionalities.
• Enzymatic activation using porcine liver esterase.
• Relaxivity measurements using a 1.5 T MRI scanner.
• Spectroscopic and computational methods to study the complex's charge and binding properties.

Main Results:

• The Gd(III) complex was successfully synthesized and demonstrated esterase-dependent activation.
• Exposure to porcine liver esterase resulted in an 84% increase in relaxivity.
• Activation led to the formation of a negative charge on the complex, which suppressed the binding of bicarbonate/carbonate ions.
• Suppression of bicarbonate/carbonate binding was identified as the primary mechanism for the observed relaxivity enhancement.

Conclusions:

• The developed Gd(III) complex serves as an effective activatable MRI contrast agent.
• Enzymatic cleavage of ester groups provides a mechanism for controlled activation and enhanced relaxivity.
• The findings highlight the potential of charge-modulated binding in designing responsive contrast agents for improved MRI sensitivity.